clobetasol and Dermatitis--Allergic-Contact

Allergic contact dermatitis (ACD) may occur secondary to topical corticosteroids. This may be due to topical corticosteroids containing potential allergens in their vehicles. Variation of allergenic ingredients among various brands of a product has not been well characterized.. This study aimed to assess the frequency of allergenic ingredients in various brands and manufacturers of clobetasol propionate.. Common brands of clobetasol propionate were identified online on GoodRx website. Then, ingredient lists for these products were obtained from the US Food & Drug Administration’s Online Label Repository via a proprietary name search. A systematic literature review was performed using the ingredient name on Medline (PubMed) database to find reports of ACD confirmed by patch testing.. Forty-nine different ingredients were identified among all 18 products included, with an average of 8.4 ingredients per product; 19 of these ingredients have allergenic potential, while one has protective effects. Two branded foam formulations contained the greatest number of potential allergens (5), while a shampoo formulation contained no potential allergens. Knowing which allergens are present in different products may be helpful when treating a patient with an allergy or suspected allergy to one of these ingredients. J Drugs Dermatol. 2023;22(5): doi:10.36849/JDD.4651.

Topics: Allergens; Clobetasol; Dermatitis, Allergic Contact; Glucocorticoids; Humans; Pharmaceutical Vehicles

Although topical glucocorticoids are effective for most inflammatory skin disorders, their use is limited by local and systemic side effects. Tacrolimus and pimecrolimus are immunomodulators that provide clinicians with steroid-sparing options in the long-term topical treatment of allergic contact dermatitis.. To obtain pilot data regarding the relative efficacies of pimecrolimus 1% cream, tacrolimus 0.1% ointment, clobetasol propionate 0.05% ointment, and triamcinolone acetonide 0.1% ointment, as compared to control preparations (Vanicream and petrolatum), for treatment of experimentally induced nickel contact dermatitis.. Twenty-one volunteers with positive patch test reactions to nickel sulfate 5% at six sites (three on each arm) applied each study medication to one nickel site, respectively, twice daily for 14 days. Study medications were prepared in identical syringes, and the site of application was randomly assigned by a computer-generated randomization schedule. Assessments were performed at 3, 7, 10, and 14 days after randomization.. Most reactions were coded as resolved or as almost resolved by day 14 regardless of treatment. Although most pairwise comparisons were not statistically significant, a clear trend was observed for sites treated with active drug to do better than control sites.. Possible explanations for these results include contamination by neighboring medication sites, timing of assessments, and lack of repeated nickel applications.

Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Allergens; Clobetasol; Dermatitis, Allergic Contact; Double-Blind Method; Female; Humans; Immunologic Factors; Male; Nickel; Petrolatum; Pilot Projects; Severity of Illness Index; Tacrolimus; Treatment Outcome; Triamcinolone

Mometasone furoate (MF) is a new strongly lipophilic steroid which has an anti-inflammatory effect as evaluated by in vivo and in vitro studies.. The objective of the present study was to investigate the degree of inhibition of experimental allergic contact dermatitis induced by the treatment with MF.. The therapeutic effect was evaluated by an echographic method associated with image analysis. MF activity was compared to that of hydrocortisone acetate 0.5% (Cortaid Cream, Lachifarma), clobetasone butyrate 0.05% (Eumovate Cream, Glaxo) and clobetasol propionate 0.05% (Clobesol Cream, Glaxo), classified respectively as weak, moderately potent and very potent steroids.. The different corticosteroid formulations employed for inhibiting experimentally induced contact dermatitis reflect the expected rank order of efficacy.. MF behaves like clobetasol butyrate ranking as a moderately potent corticosteroid.

Topics: Administration, Topical; Adolescent; Adult; Analysis of Variance; Anti-Inflammatory Agents; Clobetasol; Dermatitis, Allergic Contact; Female; Humans; Hydrocortisone; Image Enhancement; Middle Aged; Mometasone Furoate; Patch Tests; Pregnadienediols; Reproducibility of Results; Skin; Ultrasonography

Contact allergy to corticosteroids now seems frequent among patients being patch tested. As corticosteroids are intrinsically anti-inflammatory, we investigated whether patch tests with a potent corticosteroid might suppress simultaneous adjacent patch test reactions to another allergen. Nickel-sensitive subjects were patch tested with an aqueous dilution series of nickel in duplicate, adjacent to patch tests with clobetasol propionate 1% in ethanol and with ethanol, respectively. Statistical evaluation of the results obtained in 2 different centers, using their own patch test techniques, did not reveal any suppression of the positive nickel patch test reactions.

Topics: Clobetasol; Dermatitis, Allergic Contact; Drug Interactions; Ethanol; Humans; Nickel; Patch Tests; Skin

Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Antifungal Agents; Clobetasol; Dermatitis, Allergic Contact; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Imidazoles; Male; Nail Diseases; Toes

Topics: Administration, Topical; Antifungal Agents; Clobetasol; Dermatitis, Allergic Contact; Humans; Imidazoles; Male; Middle Aged; Patch Tests

As wearable devices play an increasing role in the management of health and disease, adverse skin reactions to wearables have become more common. However, the management of allergic contact dermatitis is challenging and new treatment options more compatible with wearable devices are needed. In a 40-year-old woman with contact dermatitis to a continuous glucose monitoring device, topical clobetasol propionate 0.05% spray proved to be an effective treatment that was compatible with the application of adhesive wearables. This case demonstrates that spray formulations of topical steroids are a good option for the treatment of dermatitis under wearable devices such as continuous glucose monitors or ostomy appliance.

Topics: Administration, Topical; Adult; Blood Glucose Self-Monitoring; Clobetasol; Dermatitis, Allergic Contact; Female; Humans; Receptors, Glucocorticoid; Wearable Electronic Devices

Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Chloramphenicol; Clobetasol; Dermatitis, Allergic Contact; Follow-Up Studies; Glucocorticoids; Humans; Male; Microbial Collagenase; Ointments; Patch Tests; Prurigo; Treatment Outcome; Varicose Ulcer

Erythema multiforme is a skin disorder characterised by target epithelial eruption, which is mainly caused by infection or drugs. In this case, we report an erythema multiforme like reaction caused by contact dermatitis against wood, especially santos rosewood. During the hospitalisation, we performed a patch test with lumber used in the patient's workplace, and recognised a positive response to multiple woods and a simultaneous recurring eruption (flare up) outside of the test site. The findings from this case of contact dermatitis caused by frequently used industrial wood type is important for the management of occupational environments. A review of the literature on erythema multiforme like reaction due to contact dermatitis, including past case reports, has also been provided.

Topics: Administration, Cutaneous; Adult; Clobetasol; Dermatitis, Allergic Contact; Erythema Multiforme; Fabaceae; Humans; Male; Occupational Diseases; Patch Tests; Taxaceae; Wood

Corticosteroids are among the most commonly used topical drugs. Contact allergy to these exists, but can be easily missed. Corticosteroid screening markers have been included in the baseline series with the aim of detecting most of the sensitized patients.. To assess the prevalence of contact allergy to topical corticosteroids in Spain and examine the usefulness of corticosteroid markers to detect contact allergy to corticosteroids.. In total, 3699 patients referred to 20 dermatology departments across Spain for patch testing with the baseline series, including budesonide and tixocortol pivalate, were also tested with six supplementary corticosteroids (methylprednisolone aceponate, mometasone furoate, prednicarbate, clobetasol propionate, betamethasone 17-valerate, and betamethasone 17,21-dipropionate). Additionally, 2547 (68.8%) patients were tested with hydrocortisone 17-butyrate.. Fifty-four patients showed positive reactions to at least one of all tested corticosteroids (1.46%). Thirty-nine (1.05%) reacted to at least one of the additionally tested corticosteroids; among these, 24 of 39 (61.5%) did not react to any of the corticosteroid allergy screening markers tested.. More than half of the patients who were allergic to the additionally tested corticosteroids were not detected with the corticosteroid allergy markers. An update of the corticosteroid allergy screening markers is encouraged, with consideration of group 3 corticosteroids.

Topics: Administration, Cutaneous; Adult; Betamethasone; Betamethasone Valerate; Clobetasol; Dermatitis, Allergic Contact; Dermatologic Agents; Female; Humans; Hydrocortisone; Male; Methylprednisolone; Mometasone Furoate; Patch Tests; Predictive Value of Tests; Prednisolone; Prevalence; Prospective Studies; Spain

Henna is used for coloring hair, but also to draw labile skin tattoo. Henna is often mixed with paraphenylenediamine (PPD). We report the case of a female patient presenting with contact eczema due to labile tattoo containing PPD. The study involved a 23-year old young woman with an aesthetic Black Henna tattoo on the back of the hand and on the forearm. This labile tattoo contained PPD. Two days later, the patient developed intensely pruritic, burning erythematovesiculosus and edematous lesions. The lesions involved the tattooed area, corresponding with the original drawing. The lesions were improved using Class 1 of topical corticosteroids (Clobetasol propionate). The patient refused allergy patch testing, so no allergy test was performed. Now, henna is very popular in the western countries. PPD is added to reduce the fixing time or to obtain a darker coloration. It can result in severe systemic reactions. The most frequent allergic reaction is contact dermatitis. Treatment is based on local corticosteroid therapy. A better regulation on labile tattoo, the control of preparations as well as a regular annual information for the general public are essential. The interest of our study lies in highlighting the importance of informing, especially young people, on the risks of labile tattoo.

Topics: Clobetasol; Coloring Agents; Dermatitis, Allergic Contact; Female; Glucocorticoids; Humans; Phenylenediamines; Tattooing; Young Adult

Topics: Clobetasol; Dermatitis, Allergic Contact; Glucocorticoids; Hair Dyes; Humans

Topics: Anti-Inflammatory Agents; Child; Clobetasol; Coloring Agents; Dermatitis, Allergic Contact; Humans; Male; Phenylenediamines; Tattooing

Topics: Anti-Inflammatory Agents; Clobetasol; Dermatitis, Allergic Contact; Female; Hair Preparations; Humans; Middle Aged; Plant Oils; Scalp Dermatoses

Topics: Adult; Clobetasol; Cosmetics; Dermatitis, Allergic Contact; Diagnosis, Differential; Emulsifying Agents; Female; Filaggrin Proteins; Fish Oils; Gloves, Protective; Hand Dermatoses; Hexoses; Humans; Intermediate Filament Proteins; Mutation; Ointments; Patch Tests; Skin Absorption; Young Adult

Topics: Adult; Anti-Allergic Agents; Clobetasol; Coloring Agents; Cosmetics; Dermatitis, Allergic Contact; Extremities; Female; Glucocorticoids; Humans; India; Mometasone Furoate; Patch Tests; Phenylenediamines; Pregnadienediols; Skin Diseases, Vesiculobullous; Travel

Topics: Administration, Topical; Aged; Anti-Inflammatory Agents; Clobetasol; Dermatitis, Allergic Contact; Female; Humans; Patch Tests; Sulfites

1. This study examines the relative contributions made by inhibition of mast cell degranulation, reduction of mast cell recruitment and maturation, and lowering the responsiveness of the vasculature to histamine, in the inhibition by glucocorticoids of the weal and flare in human skin. 2. One forearm of healthy human volunteers was treated for 24 h (n=6) or daily for 21 days (n=10) with 0.05% clobetasol propionate. The other arm served as control. Weal and flare responses were elicited by intradermal injection of 20 microl of 0.3 mM codeine. The areas of the responses were measured using scanning laser Doppler imaging. Microdialysis was used to assess histamine release. Mast cell numbers and tissue histamine content were assessed in 4-mm punch biopsies. Histamine (20 microl of 1 microM i.d.) was used to assess the status of the vasculature. 3. No significant effects were seen at 24 h. At 21 days, clobetasol reduced the areas of the codeine-induced weal and flare responses by 59 and 58% respectively (both P=0.006). Mast cell numbers were reduced by 47%, (P=0.014) and total tissue histamine content by 52% (P=0.006). Codeine-induced histamine release was reduced by 44% (P=0.022). The weal, but not the flare, induced by histamine was significantly inhibited (P=0.019). Echography revealed a 15% thinning of the skin by clobetasol. 4. These results demonstrate that reduction of the weal and flare responses to codeine following clobetasol treatment, results primarily from reduced mast cell numbers and tissue histamine content rather than inhibition by corticosteroids of mast cell degranulation.

Topics: Administration, Topical; Adult; Analgesics, Opioid; Anti-Inflammatory Agents; Cell Count; Clobetasol; Codeine; Dermatitis, Allergic Contact; Glucocorticoids; Histamine Release; Humans; Laser-Doppler Flowmetry; Male; Mast Cells; Skin

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Dermatitis, Allergic Contact; Humans; Male; Patch Tests

Formaldehyde-releasing preservatives are well-known allergens found in many topical preparations including medications.. To analyze the relevance of a positive patch test to formaldehyde-releasing preservatives in medications containing these preservatives.. Patients were recruited with a history of allergy to one of these preservatives. Patch and use testing to the medications, vehicles, and preservatives were performed. The following medications and their respective preservatives were used: Renova 0.05% cream/quaternium-15, Dovonex 0.005% cream/diazolidinyl urea, and Temovate-E 0.05% cream/diazolidinyl urea.. Nine patients participated in the study. A positive patch test to the preservative was reproduced in six of nine patients, and a questionable reaction occurred in one. Two patients had a positive patch test to the topical medication and one a questionable reaction. There were no definitive positive patch tests to the vehicle but two questionable ones. Use testing revealed three positive reactions to Renova, one to Renova vehicle, and one to Temovate-E vehicle.. The concentration of the preservative in the commercial preparation was often below the threshold necessary to produce a clinical reaction. Use testing is a valuable tool in the complete evaluation of the patient with a positive patch test to a formaldehyde-releasing perservative found in topical medication.

Topics: Administration, Cutaneous; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Calcitriol; Chemistry, Pharmaceutical; Clobetasol; Dermatitis, Allergic Contact; Dermatologic Agents; Double-Blind Method; Formaldehyde; Glucocorticoids; Humans; Keratolytic Agents; Methenamine; Patch Tests; Preservatives, Pharmaceutical; Tretinoin; Urea

The human skin blanching assay is a well established method for ranking the efficacy of corticosteroids after epicutaneous application. Vasoconstriction is a pharmacological activity, which correlates well with the clinical efficacy, the intensity of skin blanching after a single application under occlusion corresponding, generally, to the clinical efficacy after repeated application without occlusion. However, in studies dealing with the comparison between the vasoconstriction assay and the evaluation of the clinical effects on inflammatory skin diseases, some exceptions to this correlation have been reported. Therefore, in a pre-clinical phase, it would be useful to combine the blanching assay with at least one anti-inflammatory assay. In the present study the blanching assay and the allergic contact dermatitis inhibition test were performed in parallel, in order to compare the two testing procedures in the same group of subjects, utilizing standardized study designs supported by objective means of evaluation. Three commercial preparations of corticosteroids containing clobetasol propionate (CP), clobetasone butyrate (CB) and hydrocortisone acetate (HA), respectively, were employed both to treat nickel-induced positive patch test responses on the volar forearms, and to perform a vasoconstrictor assay on normal forearm skin in 16 nickel-sensitized healthy volunteers. For evaluating skin blanching, we employed colorimetric measurements, whereas for the quantitative determination of the inhibition of the intensity of allergic patch test reactions, 20 MHz B-scanning supported by image analysis was used. Both colorimetric and echogenicity values enabled us to distinguish between the three corticosteroids (at the 17 h evaluation and the 64 h assessment, respectively). A fair correlation was noted between colorimetric and echogenicity values. Both testing procedures ranked the three corticosteroids in the expected order. Corticosteroid preparations should be compared using methods which allow different effects to be simultaneously monitored, without involving a high number of patients. We are proposing this double procedure for the parallel intraindividual evaluation of the vasoconstrictory action and the anti-allergic activity of topical steroids.

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Clobetasol; Colorimetry; Dermatitis, Allergic Contact; Drug Evaluation; Female; Humans; Hydrocortisone; Image Processing, Computer-Assisted; Male; Nickel; Patch Tests; Skin; Ultrasonography; Vasoconstriction; Vasoconstrictor Agents

Topics: Aged; Anti-Inflammatory Agents; Clobetasol; Dermatitis, Allergic Contact; Female; Hexoses; Humans; Hydrocortisone; Patch Tests; Surface-Active Agents